Recurrent heart failure with preserved ejection fraction associated with carfilzomib administration for multiple myeloma

Carfilzomib, an epoxyketone proteasome inhibitor, has demonstrated improved progression-free survival in patients when used with standard treatment (lenalidomide and dexamethasone) in patients with relapsed multiple myeloma (MM). However, there are reports of adverse cardiac events with carfilzomib...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Eric H., Courtney, Cynthia, Garg, Vinisha, Fradley, Michael G., Schiller, Gary J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Short Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7048019/
https://www.ncbi.nlm.nih.gov/pubmed/32154003
http://dx.doi.org/10.1186/s40959-018-0028-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7048019/
https://www.ncbi.nlm.nih.gov/pubmed/32154003
http://dx.doi.org/10.1186/s40959-018-0028-z

Ejemplares similares